查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552602

核酸治療 CDMO 市場規模、佔有率和趨勢分析報告：按類型、服務、最終用途、應用、地區和細分市場預測，2024-2030 年

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

核酸療法 CDMO 市場成長與趨勢：

根據Grand View Research, Inc.最新報告，預計到2030年，全球核酸治療CDMO市場規模將達到338.6億美元，預測期內複合年成長率為14.10%。

推動該市場成長的主要因素包括對核酸治療藥物的需求增加、核酸技術的進步以及 FDA 對核酸治療藥物的核准增加，從而導致對具有成本效益的合約開發和受託製造服務的需求不斷成長。

生技公司、製藥公司和學術機構對基因治療研發的投資和興趣不斷增加，正在推動對 CDMO 服務的需求。 CDMO 在基因治療製造中發揮重要作用。例如，作為 Sarepta Therapeutics 的商業製造合作夥伴，Catalent 在推進基因治療解決方案方面發揮關鍵作用。

mRNA 疫苗在應對 COVID-19 大流行方面的成功證明了核酸療法的潛力，並刺激了該領域的進一步研究和投資。例如，賽諾菲在 2022 年 3 月宣布，將在未來幾年內投入 10.2 億美元（9.35 億歐元）在法國開發傳訊RNA疫苗。賽諾菲將在 2026 年之前進行這項投資，作為 2021 年 6 月宣布的 20 億歐元全球投資舉措的一部分。這項舉措旨在進一步推進公司的 mRNA 策略。這種增資情境將促進市場成長。

此外，越來越多的 CDMO 收購和合作預計將在未來幾年加速核酸治療 CDMO 市場的成長。例如，2022 年 5 月，eureKARE 進行了價值 1.6098 億美元（1.5 億歐元）的合併，以創建一個細胞和基因治療合約開發和製造組織 (CDMO)。

該公司成立了特殊目的收購公司 eureKING (SPAC)，以整合三個歐洲合約開發和受託製造廠商(CDMO)。此外，2022 年 4 月，FUJIFILM將透過收購位於加州 Atara Biotherapeutics, Inc. 的一家專門從事細胞治療的製造工廠，擴大其作為先進療法合約開發和受託製造廠商(CDMO) 的產品組合。此類舉措預計將促進市場成長。

核酸療法 CDMO 市場報告亮點

  • 2023 年，基於 RNA 的治療領域佔據了最大的收益佔有率。基於 RNA 的療法（主要是 mRNA）提供了解決多種疾病的多功能性。它們可以被設計為產生多種治療性蛋白質，從而適用於不同的治療領域。
  • 預計未來幾年基因治療領域的市場將顯著成長。這歸功於基因治療的臨床成功，並有助於擴大基因治療的適應症。
  • 2023年，製造業服務業佔據市場主導地位，佔總銷售佔有率超過38.37%。促進該行業成長的主要挑戰包括複雜的製造流程、規模化和生產挑戰以及成本效率。
  • 生技公司在2023年佔據領先的收益佔有率，超過58%，因為它們大力投資於創新治療方法的研發。
  • 2023年，北美在核酸治療CDMO市場中佔據最大收益佔有率，達到40.24%。大量的投資和資金、強大的學術和研究機構以及 CDMO 的全球擴張正在推動該地區的成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章 核酸治療 CDMO 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 配套市場前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 2023 年臨床試驗數量分析
    • 按地區分類的臨床試驗總數（2023 年）
    • 臨床試驗總數（按階段）（2023年）
    • 臨床試驗總數（依研究設計）（2023）
    • 按主要治療領域分類的臨床試驗總數（2023 年）
  • 核酸治療 CDMO 市場：分析工具
    • 波特五力分析
    • PESTEL分析
  • COVID-19 影響分析

第4章 核酸治療 CDMO 市場：按類型估計和趨勢分析

  • 細分儀表板
  • 全球核酸治療CDMO市場波動分析
  • 2018-2030年全球核酸治療CDMO市場規模及趨勢分析（按類型）
  • 基因治療
  • 基於RNA的治療方法

第5章 核酸治療藥物CDMO市場：依服務估算及趨勢分析

  • 細分儀表板
  • 全球核酸治療CDMO市場波動分析
  • 2018-2030年全球核酸治療CDMO市場規模及趨勢分析（依服務）
  • 製程開發與最佳化
  • 製造服務
  • 分析和品管服務

第6章 核酸治療 CDMO 市場：依最終用途分類的估算與趨勢分析

  • 細分儀表板
  • 全球核酸治療CDMO市場波動分析
  • 2018-2030年全球核酸治療CDMO市場規模與趨勢分析（依最終用途）
  • 製藥公司
  • 政府及學術研究機構
  • 生技公司

第7章 核酸治療 CDMO 市場：依應用估算與趨勢分析

  • 細分儀表板
  • 全球核酸治療CDMO市場波動分析
  • 2018年至2030年全球核酸治療CDMO市場規模及趨勢分析（依應用）
  • 罕見疾病
    • 2018 年至 2030 年市場估計與預測
  • 遺傳疾病
    • 2018 年至 2030 年市場估計與預測
  • 感染疾病
    • 2018 年至 2030 年市場估計與預測
  • 其他
    • 2018 年至 2030 年市場估計與預測

第8章 核酸治療CDMO市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018 年至 2030 年市場估計與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018 年至 2030 年市場估計與預測
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 2018 年至 2030 年市場估計與預測
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 2018 年至 2030 年市場估計與預測
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 2018 年至 2030 年市場估計與預測
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 市場參與企業分類
    • 市場領導者
    • 新興玩家
  • 按行業分類的競爭市場佔有率（2023 年）
  • 競爭地圖：依服務類型分類（2023）
  • 服務熱圖分析（公司比較分析）
  • 公司簡介
    • Agilent Technologies, Inc
    • Curia Global, Inc.
    • Ajinomoto Co., Inc.
    • Danaher Corporation
    • KNC Laboratories Co., Ltd.
    • LGC Limited
    • Merck KGaA
    • WuXi AppTec
    • BIOSPRING
    • Exothera
Product Code: GVR-4-68040-125-4

Nucleic Acid Therapeutics CDMO Market Growth & Trends:

The global nucleic acid therapeutics CDMO market size is expected to reach USD 33.86 billion by 2030, registering a CAGR of 14.10% during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.

Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.

The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.

Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).

The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.

Nucleic Acid Therapeutics CDMO Market Report Highlights:

  • The RNA-based therapies segment held the largest revenue share in 2023. RNA-based therapies, mainly mRNA, offer versatility in addressing various diseases. They can be designed to produce a variety of therapeutic proteins, making them applicable to diverse therapeutic areas.
  • The gene therapy segment is expected to show significant market growth in the coming years. This is attributed to the clinical success of gene therapies, which have helped in expanding indications of gene therapies.
  • In 2023, the manufacturing services segment dominated the market, accounting for over 38.37% of the total revenue share. Key factors contributing to segment growth include complex manufacturing processes, scale-up & production challenges, and cost efficiency.
  • The biotechnology companies held a major revenue share of over 58% in 2023 due to substantial investments in the research and development of innovative therapies.
  • North America held the largest revenue share of 40.24% in the nucleic acid therapeutic CDMO market in 2023. Substantial investments and funding support, strong academic and research institutions, and global expansion of CDMOs drive regional growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Regional Scope
    • 1.1.2. Estimates and Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Purchased Database
    • 1.3.3. GVR's Internal Database
    • 1.3.4. Secondary Sources
    • 1.3.5. Primary Research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Validation
    • 1.5.1. Region Wise Market: Base Estimates
    • 1.5.2. Global Market: CAGR Calculation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis (Model 1)
    • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
    • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
    • 1.6.4. Bottom-Up Approach (Model 4)
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Nucleic Acid Therapeutics CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising incidence of genetic disorders across the globe
      • 3.2.1.2. Robust expansion of the genomics research sector and strong traction gained by custom oligonucleotides
      • 3.2.1.3. Increasing demand for one-stop-shop CDMOs and growing foreign direct investments in nucleic acid therapeutics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited outsourcing by big pharmaceutical and biopharmaceutical companies
      • 3.2.2.2. Stringent regulatory framework
  • 3.3. Clinical Trials Volume Analysis, 2023
    • 3.3.1. Total Number of Clinical Trials, by Region (2023)
    • 3.3.2. Total Number of Clinical Trials, by Phase (2023)
    • 3.3.3. Total Number of Clinical Trials, by Study Design (2023)
    • 3.3.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
  • 3.4. Nucleic Acid Therapeutics CDMO Market: Analysis Tools
    • 3.4.1. Porter's Five Forces Analysis
    • 3.4.2. PESTEL Analysis
  • 3.5. COVID-19 Impact Analysis

Chapter 4. Nucleic Acid Therapeutics CDMO Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 4.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Gene Therapy
    • 4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 4.5. RNA-based Therapies
    • 4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 5. Nucleic Acid Therapeutics CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 5.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
  • 5.4. Process Development and Optimization
    • 5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.5. Manufacturing Services
    • 5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 5.6. Analytical and Quality Control Services
    • 5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 6. Nucleic Acid Therapeutics CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 6.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.5. Government & Academic Research Institutes
    • 6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 6.6. Biotech Companies
    • 6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 7. Nucleic Acid Therapeutics CDMO Market: Application Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
  • 7.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, Application, 2018 to 2030 (USD Million)
  • 7.4. Rare Diseases
    • 7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.5. Genetic Disorders
    • 7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.6. Infectious Diseases
    • 7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 8. Nucleic Acid Therapeutics CDMO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Global Regional Market Snapshot
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Scenario
      • 8.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Scenario
      • 8.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Scenario
      • 8.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Scenario
      • 8.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Scenario
      • 8.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Scenario
      • 8.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Scenario
      • 8.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Scenario
      • 8.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Scenario
      • 8.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Scenario
      • 8.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Scenario
      • 8.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Scenario
      • 8.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.3. Japan
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Scenario
      • 8.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Scenario
      • 8.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Scenario
      • 8.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Scenario
      • 8.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Scenario
      • 8.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Scenario
      • 8.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Scenario
      • 8.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Scenario
      • 8.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Scenario
      • 8.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Scenario
      • 8.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Scenario
      • 8.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Market Leaders
    • 9.1.2. Emerging Players
  • 9.2. Competitive Market share, by Industry (2023)
  • 9.3. Competition Mapping by Service Type (2023)
  • 9.4. Service Heat Map Analysis (a comparative analysis of the players together)
  • 9.5. Company Profiles
    • 9.5.1. Agilent Technologies, Inc
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Service Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Curia Global, Inc.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Service Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Ajinomoto Co., Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Service Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Danaher Corporation
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Service Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. KNC Laboratories Co., Ltd.
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Service Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. LGC Limited
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Service Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Merck KGaA
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Service Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. WuXi AppTec
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Service Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. BIOSPRING
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Service Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Exothera
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Service Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 4 Global Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 5 Global Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 6 Global Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 7 Global Nucleic Acid Therapeutics CDMO, by Region, 2018 - 2030 (USD Million)
  • Table 8 North America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 9 North America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 10 North America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 11 North America Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 12 North America Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 13 U.S Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 14 U.S Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 15 U.S Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 16 U.S Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 17 Canada Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 18 Canada Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 19 Canada Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 20 Canada Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 21 Mexico Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 22 Mexico Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 23 Mexico Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 24 Mexico Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 25 Europe Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 26 Europe Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 27 Europe Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 28 Europe Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 29 Europe Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 30 Germany Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 31 Germany Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 32 Germany Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 33 Germany Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 34 UK Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 35 UK Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 36 UK Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 37 UK Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 38 France Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 39 France Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 40 France Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 41 France Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 42 Italy Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 43 Italy Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 44 Italy Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 45 Italy Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 46 Spain Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 47 Spain Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 48 Spain Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 49 Spain Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 50 Denmark Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 51 Denmark Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 52 Denmark Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 53 Denmark Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 54 Sweden Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 55 Sweden Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 56 Sweden Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 57 Sweden Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 58 Norway Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 59 Norway Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 60 Norway Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 61 Norway Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 67 China Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 68 China Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 69 China Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 70 China Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 71 Japan Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 72 Japan Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 73 Japan Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 74 Japan Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 75 India Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 76 India Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 77 India Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 78 India Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 79 South Korea Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 80 South Korea Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 81 South Korea Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 82 South Korea Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 83 Australia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 84 Australia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 85 Australia Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Australia Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 87 Thailand Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 88 Thailand Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 89 Thailand Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 90 Thailand Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 91 Latin America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 92 Latin America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 93 Latin America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 94 Latin America Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 95 Latin America Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 96 Brazil Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 97 Brazil Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 98 Brazil Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 99 Brazil Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 100 Argentina Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 101 Argentina Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 102 Argentina Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 103 Argentina Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 108 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 109 South Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 110 South Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 111 South Africa Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 112 South Africa Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 117 UAE Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 118 UAE Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 119 UAE Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 120 UAE Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
  • Table 121 Kuwait Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 123 Kuwait Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 124 Kuwait Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Nucleic Acid Therapeutics CDMO Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 10 Porter's Five Forces Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Nucleic Acid Therapeutics CDMO, for Gene Therapy, 2018 - 2030 (USD Million)
  • Fig. 13 Global Nucleic Acid Therapeutics CDMO, for RNA-based Therapies, 2018 - 2030 (USD Million)
  • Fig. 14 Global Nucleic Acid Therapeutics CDMO, for Process Development and Optimization, 2018 - 2030 (USD Million)
  • Fig. 15 Global Nucleic Acid Therapeutics CDMO, for Manufacturing Services, 2018 - 2030 (USD Million)
  • Fig. 16 Global Nucleic Acid Therapeutics CDMO, for Analytical and Quality Control Services, 2018 - 2030 (USD Million)
  • Fig. 17 Global Nucleic Acid Therapeutics CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 18 Global Nucleic Acid Therapeutics CDMO, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Nucleic Acid Therapeutics CDMO, for Government & Academic Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 20 Global Nucleic Acid Therapeutics CDMO, for Biotech Companies, 2018 - 2030 (USD Million)
  • Fig. 21 Global Nucleic Acid Therapeutics CDMO, for Rare Diseases, 2018 - 2030 (USD Million)
  • Fig. 22 Global Nucleic Acid Therapeutics CDMO, for Genetic Disorders, 2018 - 2030 (USD Million)
  • Fig. 23 Global Nucleic Acid Therapeutics CDMO, for Infectious Diseases, 2018 - 2030 (USD Million)
  • Fig. 24 Global Nucleic Acid Therapeutics CDMO, for Others, 2018 - 2030 (USD Million)
  • Fig. 25 Regional Outlook, 2023 & 2030
  • Fig. 26 North America Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Canada Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Mexico Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Europe Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Germany Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 UK Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 France Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Italy Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Spain Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Denmark Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Norway Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Asia Pacific Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Japan Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 China Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 India Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Australia Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 South Korea Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Thailand Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Latin America Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Brazil Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Argentina Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Middle East and Africa Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 South Africa Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Saudi Arabia Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 UAE Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Kuwait Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)